Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A new startup called Surzen Biotherapeutics is taking a fresh approach to pain management — one that could make opioids safer. Founded out of Japan's Okinawa Institute of Science and Technology, the company uses patented peptides to block opioid receptor dimerization, potentially reducing addiction, tolerance, and overdose risks while keeping pain relief effective.
A new startup wants to make opioids safer — without sacrificing their effectiveness.
Surzen Biotherapeutics, launching from the Okinawa Institute of Science and Technology (OIST), is developing a peptide-based technology designed to address the well-known dangers of opioid pain management. The science centers on opioid receptor dimerization — a process where two receptor molecules bond together, which is linked to the side effects of traditional opioid drugs. By identifying peptides that block this dimerization, the company aims to co-administer them alongside conventional opioids to reduce tolerance, improve efficacy, and cut down on severe side effects like addiction and respiratory depression.
The startup was co-founded by Dr. Peng Zhou, whose motivation stems from watching his father suffer through late-stage cancer pain, and James Feliciano, a veteran pharmaceutical executive. Backed by seed funding from Saisei Ventures and a grant from the Okinawa Prefectural Government, the team is eyeing global markets — especially the U.S. and Canada, where the opioid crisis remains acute.
By the Numbers:
Why it matters: With opioids still the go-to option for severe and chronic pain, a safer alternative could be transformative — both for patients and for overstretched healthcare systems grappling with the ongoing overdose epidemic.
